close
close

Voice News

CA News 2024

searchengine

Amylyx Pharma’s Analysis: 9 Analysts Share Their Opinions – Amylyx Pharma (NASDAQ:AMLX)


20-Year-Old Professional Trader Unveils His “MoneyLine”

Throw away your indicators and use the “MoneyLine”. A simple rule tells you when to buy and sell without the guesswork. It’s a line on a chart that has helped Nic Chahine win 83% of his options buys. Here’s how he does it.


Amylyx Pharma (NASDAQ:AMLX) underwent analysis by 9 analysts last quarter, which revealed a spectrum of views from bullish to bearish.

The following table summarizes their recent ratings, sheds light on the changing sentiments over the past 30 days, and compares them to the previous months.

Bullish Somewhat bullish Indifferent Somewhat bearish Bearish
Total reviews 6 0 3 0 0
Last 30D 1 0 0 0 0
1 million ago 1 0 1 0 0
2M ago 3 0 2 0 0
3M ago 1 0 0 0 0

Insights from analysts’ 12-month price targets are revealed, with an average price target of $9.22, a high estimate of $32.00 and a low estimate of $3.00. The current average indicates a downside of 66.73% and is down from the previous average price target of $27.71.

Interpreting analyst ratings: A closer look

An extensive investigation into how financial experts perceive Amylyx Pharma is derived from recent analyst actions. The following is a detailed overview of the top analysts, their recent evaluations and adjustments to ratings and price targets.

Analyst Analyst firm Measures taken Judgement Current price target Prior price target
Andreas Fein HC Wainwright & Co. Maintains To buy $8.00
Joel Beatty Baird Lowers Neutral $3.00 $4.00
Andreas Fein HC Wainwright & Co. Maintains To buy $8.00
Andreas Fein HC Wainwright & Co. Maintains To buy $8.00 $8.00
Andreas Fein HC Wainwright & Co. Lowers To buy $8.00 $42.00
Neena Bitritto-Garg German Bank Lowers To buy $8.00 $36.00
Chris Shibutani Goldman Sachs Lowers Neutral $4.00 $40.00
Joel Beatty Baird Lowers Neutral $4.00 $37.00
Graig Suvannavejh Mizuho Increases To buy $32.00 $27.00

Key insights:

  • Measures taken: In response to changing market dynamics and business performance, analysts update their recommendations. Whether they ‘maintain’, ‘increase’ or ‘decrease’ their position, it signifies their response to recent developments regarding Amylyx Pharma. This provides insight into analysts’ perspectives on the current state of the company.
  • Judgement: Analysts assign qualitative ratings to stocks ranging from ‘Outperform’ to ‘Underperform’. These ratings reflect analysts’ expectations about Amylyx Pharma’s relative performance compared to the broader market.
  • Price targets: Analysts dig into moves and provide estimates for the future value of Amylyx Pharma’s stock. This analysis reveals shifts in analyst expectations over time.

Gain valuable insights into Amylyx Pharma’s market position by understanding these analyst ratings and relevant financial indicators. Stay informed and make strategic decisions with our assessment table.

Stay up to date with Amylyx Pharma analyst reviews.

If you’re interested in following the news and performance of small cap stocks, you can start here.

Dive into the background of Amylyx Pharma

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company developing a novel therapeutic agent for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment dedicated to researching and developing therapies for neurodegenerative diseases.

Financial Insights: Amylyx Pharma

Market Capitalization Analysis: The company’s market capitalization, which is below industry benchmarks, reflects a smaller size compared to peers. This positioning can be influenced by factors such as growth expectations or operational capacity.

Sales growth: Amylyx Pharma’s remarkable performance in 3 months is clear. As of December 31, 2023, the company achieved impressive revenue growth of 395.54%. This means a significant increase in the company’s turnover. Compared to its peers, the company achieved a growth rate that was higher than the average for healthcare industry peers.

Net margin: Amylyx Pharma’s net margin exceeds industry benchmarks and extends beyond 4.36%. This means efficient cost management and strong financial health.

Return on Equity (ROE): Amylyx Pharma’s ROE exceeds industry benchmarks and reaches 1.11%. This means robust financial management and efficient use of equity.

Return on Assets (ROA): The company’s ROA is performing excellently and exceeding industry averages. With an impressive ROA of 0.96%, the company shows effective use of assets.

Debt management: The company uses a balanced debt approach, with a debt-to-equity ratio below industry norms 0.01.

Analyst Ratings: Simplified

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts can attend company conference calls and meetings, research companies’ financial statements, and communicate with insiders to publish “analyst ratings” for stocks. Analysts typically rate each stock once a quarter.

Some analysts will also make forecasts for metrics such as growth estimates, earnings, and revenue to provide further guidance for stocks. Investors using analyst ratings should note that this specialized advice is human-sourced and may contain errors.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.


20-Year-Old Professional Trader Unveils His “MoneyLine”

Throw away your indicators and use the “MoneyLine”. A simple rule tells you when to buy and sell without the guesswork. It’s a line on a chart that has helped Nic Chahine win 83% of his options buys. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OF CRYPTO

Enter your email and you’ll also receive Benzinga’s Ultimate Morning Update AND a Free $30+ Gift Card!

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.